US2013331553A1PendingUtilityA1
Human toll homologues
Est. expiryOct 17, 2017(expired)· nominal 20-yr term from priority
C07K 16/2896C07K 16/28
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.
Claims
exact text as granted — not AI-modified1 .- 40 . (canceled)
41 . An isolated antibody which binds to a PRO358 polypeptide consisting essentially of amino acids 1 to 811 encoded by SEQ ID NO:14.
42 . The antibody of claim 41 wherein said antibody is a monoclonal antibody.
43 . The antibody of claim 42 wherein said antibody is one of a chimeric, humanized, and human antibody.
44 . The antibody of claim 42 wherein said antibody blocks binding of said polypeptide to one of a Gram-negative and Gram-positive organism.
45 . An isolated antibody which specifically binds to a-PRO358 polypeptide consisting essentially of amino acid residues 20 to 575 of FIG. 3 (SEQ ID NO: 13).
46 . The antibody of claim 45 wherein said antibody is a monoclonal antibody.
47 . The antibody of claim 46 wherein said antibody is one of a chimeric, humanized, and human antibody.
48 . An isolated antibody which binds to a PRO358 polypeptide consisting essentially of:
(a) amino acids 1 to 811 encoded by SEQ ID NO: 14, or (b) amino acid residues 20 to 575 of SEQ ID NO: 13; wherein said antibody is an agonist or an antagonist of NF-KB activation.
49 . The antibody of claim 48 , wherein said antibody is an agonist of NF-KB activation.
50 . The antibody of claim 48 , wherein said antibody is an antagonist of NF-KB activation.
51 . An isolated antibody which specifically binds to a-PRO358 polypeptide consisting essentially of amino acid residues 1 to 811 of FIG. 3 (SEQ ID NO: 13).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.